Clinical Trial Update: Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial assessing adoptive immunotherapy with genetically modified T-lymphocytes for recurrent or refractory high-grade malignant glioma has completed. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• High-grade Glioma

Drugs mentioned

• Genetically Modified T-Lymphocyte Therapy

Snippet

Sponsor: City of Hope Medical Center | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED